Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Governments must showcase potential of HPV vaccines in cervical cancer to fight vaccine hesitancy

Following the latest research published in The Lancet highlighting the potential impact HPV vaccinations could have on cervical cancer rates, James Mather, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Research continues to demonstrate that population-wide impact of Human papillomavirus (HPV) vaccinations is significantly reducing the prevalence of HPV. […]
Read more

Dupixent boost from FDA approval will see drug achieve blockbuster status in 2019 and estimated sales of $6.4bn in 2025

Following the news that the FDA has approved Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis, Philippa Salter, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Dupixent is the first biologic to be approved for the treatment of chronic rhinosinusitis with nasal polyposis, beating rivals in gaining market approval […]
Read more

Lack of reimbursement will limit the impact of digital therapeutics in global healthcare market

A major barrier to the widespread use of digital therapeutics (DTx) is the limitation or lack of reimbursement by public and private health insurance providers, says GlobalData, a leading data and analytics company. Digital Therapeutics (DTx) have been defined by the Digital Therapeutics Alliance (DTA) as “delivering evidence based therapeutic interventions to patients, that are […]
Read more

Roche’s Xofluza shows promise in flu prevention

Following the recent news that Roche’s Phase III influenza drug Xofluza met its primary endpoint for influenza prevention, Philipp Rosenbaum, Pharma Analyst at GlobalData, a leading data and analytics company, offers his perspective: “Given that seasonal influenza vaccines were only around 45% effective over the past 10 influenza seasons, a prophylactic label expansion for Xofluza could […]
Read more

Novavax’s ResVax at risk of losing first-to-market lead in RSV vaccines

Following the recent news that the FDA has recommended an additional Phase III trial for Novavax’s vaccine to prevent medically significant RSV disease in infants, Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his perspective: “After a string of late-stage clinical disappointments in trials of both elderly adults and pregnant […]
Read more

Following NICE recommendation, Prevymis set to exceed $5.6m peak year sales in UK

Following the recent news that NICE has recommended Merck’s Prevymis for preventing cytomegalovirus (CMV) reactivation in recipients of hematopoietic stem cell transplantation (HSCT), Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his perspective: “NICE’s revised recommendation is a major commercial win for Merck that will allow Prevymis to be funded […]
Read more

With approval of Merck’s V920 still months away, J&J’s Ebola vaccine finds elevated role in DRC outbreak

Following the recent news that Congolese Health Minister Oly Ilunga Kalenga is pushing for licensure and exclusive use of Merck’s Ebola vaccine in the current DRC outbreak, Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his perspective: “Successful delivery of vaccines to an outbreak depends on local capacity, transmission […]
Read more

Added funding provides boost for Vedanta’s experimental microbiome drug

Following the news that microbiome therapeutics developer Vedanta has completed an extended $45.5m series C round, Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “The additional funding that Vedanta secured for its series C round will support the company through Phase II clinical development of its microbiome-targeted […]
Read more

Global surgical adhesion barriers market to reach $1.4bn by 2028

The global surgical adhesion barriers market is expected to grow at a compound annual growth rate (CAGR) of 3% to reach $1.4bn by 2028, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘Surgical adhesion barriers – Wound Care Market Analysis and Forecast Model’ reveals that Asia-Pacific will be one of […]
Read more

After Phase III data, Novavax’s ResVax approval for RSV remains uncertain

Following the release of additional Phase III clinical trial (Prepare) data of Novavax’s ResVax, presented at the World Vaccine Congress in Washington, D.C., Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, discusses what the results mean for Novavax’s maternal RSV vaccine: “Despite the stated commitment from Novavax to continue commercialization efforts […]
Read more
1 … 106 107 108 109 110